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Abstract 
Diabetes mellitus is a chronic disease and one of the most important public health challenges 
facing mankind. Fagonia cretica L. (Zygophyllaceae) is a medicinal plant used widely in the 
Punjab in Pakistan. A recent survey has demonstrated that traditional healers and herbalists 
frequently use this plant to treat diabetes. In the current study, the traditional medicine was 
prepared as a tea and the profile of the main metabolites present in the traditional medicine was 
analysed via LC/MS/MS. The extract was shown to contain a number of phenolic glycosides 
including quercetin-3-O-rutinoside, kaempferol-3-O-rutinoside, kaempferol-3-O-glycoside, 
kaempferol-3(6’-malonylglucoside), isorhamnetin-3-O-rutinoside, and isorhamnetin-3-(6’’-
malonylglucoside) in addition to unidentified sulphonated saponins. The traditional medicine 
inhibits α-glucosidase in vitro with an IC50 of 4.62 µg/ml. The hypoglycaemic effect of the 
traditional medicine was evaluated in normoglycaemic and streptozotocin-treated diabetic rats, 
using glibenclamide as internal control. The preparation (250 or 500 mg/kg body weight) was 
administered once a day for 21 consecutive days. The dose of 500 mg/kg was effective in the 
management of the disease, causing a 45% decrease in plasma glucose level at the end of the 
experimental period. Histological analysis of pancreatic sections confirmed that 
streptozotocin/nictotinamide treatment caused destruction of pancreatic islet cells, while 
pancreatic sections from treatment groups showed that both the extract and glibenclamide 
partially prevented this deterioration. The mechanism of this protective effect is not clear. 
However, such a finding suggests that ingestion of the tea could confer additional benefits and 
should be investigated further.  
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Introduction 
DM is a metabolic disorder caused by either an absolute or relative lack of insulin activity and is 
characterised by an increased level of blood glucose leading to thirst and diuresis [1]. Further, it 
is associated with long term micro vascular and macro vascular complications, such as diabetic 
retinopathy, neuropathy, nephropathy and many others [2]. The rate of occurrence of DM is 
escalating and has more than doubled globally since the early 1990’s with a 35.4 million people 
suffering from the disease in the MENA region of which Pakistan contributes 7.02 million 
diabetics [3]. The predicted increase in numbers of sufferers is 51.4% in Pakistan compared with 
a regional increase of 39.2% over a single generation gap. This imposed a financial burden of 
USD. 17.1 billion spent on the management of diabetes in the region during 2015 [4]. Lifestyle 
changes for the management of type 2 DM include diet and exercise while groups including the 
AACE, the Dutch College of General Practitioners and the IDF advocate AGI’s as first line 
therapy for its treatment [5,6,7]. AGIs act by inhibition of alpha glucosidase enzymes and 
fermentation of colonic starch and specifically target the postprandial hyperglycaemia [8, 9]. 
New classes of anti-diabetic drugs such as DPP-4 inhibitors, GLP-1 analogues and combined 
receptor type 1 antagonists have been introduced in recent years. Studies have shown that the 
combined administration of AGIs and DPP-4 inhibitors result in significant decrease in plasma 
glucose fluctuations and are effective in reducing post prandial glycaemic excursions [10, 11]. 
Other therapies for diabetes include the drugs that act as secretagogues or sensitisers of beta cells 
or by the inhibition of gluconeogenesis [12]. 
Over 70% of the population in countries like Pakistan still depend on TM options (Unani, 
Ayurvedic) for their primary care [13], particularly in rural areas. This is due to a number of 
factors such as inadequate or limited access to the modern medical systems and affordability. In 
addition Unani, Ayurveda, and homeopathy have been accepted and integrated into the national 
health system in Pakistan and are widely used throughout the country. There are approximately 
52,600 registered Unani medical practitioners that serve the nation through both the public and 
private sectors in urban and rural areas [13, 14]. An extensive survey among traditional healers 
and herbalists in in the city of Bahawalpur and the Cholistan Desert in Pakistan was carried out 
comprising of 99 informants during 2011 and 2012. This study collected data relating to the use 
of medicinal flora for the treatment of diabetes [15]. The traditional healers and herbalists in this 
study claimed to diagnose DM in their patients by observing symptoms such as weight loss, 
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fatigue, excessive urination and the presence of sugar in the urine. Fagonia Cretica L. (family 
Zygophyllaceae) was frequently mentioned and highly recommended by both the traditional 
healers and rural dwellers.  
The genus Fagonia is composed of circa 35 different species, which are distributed across 
tropical, subtropical and arid areas of the world and on all continents except Australia [16]. 
Several Fagonia species feature in Asian TM systems including Ayurveda and Unani [17, 18].  F. 
cretica L. is found in North Africa, Spain, Cyprus, Turkey, and Saudi Arabia and throughout the 
desert regions of western India and Pakistan [16]. A wide range of therapeutic uses have been 
recently reviewed for F. cretica L., including anti-tumor, anti-inflammatory and neuroprotective 
have recently been reviewed [17]. There only reports for the traditional use of F. cretica L. in the 
treatment of diabetes cite its use as part of a multi-herbal mixture, where it is used in equal 
quantities with aerial parts of Aloe vera and F. Tylophorahirsuta L. combined as an aqueous 
extract [19, 20]. 
Crude phytochemical extracts and isolated compounds from F. cretica L. have been shown to 
have a diverse range of biological activities including amongst others anti-haemorrhagic, anti-
tumor, anti-inflammatory and neuroprotective cytotoxic anti-inflammatory and neuroprotective 
[21, 22, 23, 24]. Active metabolites including the anti-inflammatory and anti-tumour triterpenes 
taraxerol and ursolic acid [25, 26], and triterpenoid saponins with hederagenin and ursolic acid 
and oleanoic acid aglycones have been isolated and the general presence of flavonoids has been 
demonstrated [27, 28, 29]. In 2012, Lam et al. [30] demonstrated that an aqueous extract of F. 
cretica L. induces DNA damage, cell arrest and apoptosis in MCF-7 (WT-p53) and MDA-MB-
231 (mutant –p53) breast cancer cells. However, despite the interesting results presented in this 
study, there is no chemical fingerprint or characterisation of the extract investigated. More 
recently Saleem et al. [31]  isolated quinovic acid, quinovic acid-3β-O-β-d-glycopyranoside, 
quinovic acid-3β-O-β-d-glucopyranosyl-(28→1)-β-d-glucopyranosyl ester from F. cretica L. and 
have identified them as potential as potential DPP-4 inhibitors which might have use in the 
treatment of diabetes and may explain in part the reported use of the TM in the treatment of DM. 
Despite the body of phytochemical information that exists around F. cretica L. and the 
well acknowledged differences in metabolomic composition of herbal materials that can be 
caused by cultivation, environment and other factors [32, 33] no study to date using this TM has 
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reported on the metabolomics profile. In this study, the chemical fingerprint for the TM of F. 
cretica L. has been generated by LC/MS/MS, and this profile directly corresponds to the TM 
which shows positive effects in in vivo and in vitro models of diabetes. 
 
Materials and Methods 
 
Chemicals  
Streptozotocin (purity ≥ 95% by HPLC) was purchased from Calibiochem® (EMD Chemicals, 
San Diego, CA, USA), Nicotinamide (purity ≥ 99% by HPLC) was purchased from Acer 
Scientific (USA) and Glibenclamide (purity ≥ 99% by HPLC) and D-glucose from Sigma (St. 
Louis, MO, USA). HbA1c, creatinine, urea, ALT and AST test kits were purchased from Merck 
(Pakistan). All other chemicals and reagents used were of analytical grade. 
 
Plant Materials  
The fresh aerial parts of the Fagonia Cretica L. (Zygophyllaceae) were collected after monsoon 
during the month of May in 2012 from an area of abundant plant growth named Laatan Shinghar 
in the Cholistan Desert, district Bahawalpur, Punjab, Pakistan. The taxonomic identification of 
the plant was carried out by Prof. Dr. Muhammad Arshad Choudhary (Late), Director, Cholistan 
Institute of Desert Studies (CIDS), Islamia University of Bahawalpur (IUB) and Pakistan. The 
voucher specimens (3401/CIDS/IUB) for the plant were prepared and deposited at the herbarium 
of CIDS, IUB.  
 
Preparation of the Extract  
Fresh plant material (2.0 Kg) was washed with tap water to remove the dust and other foreign 
particles and dried under shade. The dried plant material was chopped into small pieces (1x1 cm 
approx.) and extracted with boiling water (2 L) overnight as practiced by the local informants. 
The aqueous extract was cooled and lyophilized. The percent yield of the lyophilized powder 
was 10.15% of the dry plant material. 
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LC-MS/MS analysis 
Chromatographic separations were performed on a Dionex Ultimate 3000 RS liquid 
chromatography system on a Dionex Acclaim RSLC 120 C18 column (2.1 × 100 mm, 2.2 μm) 
with a binary gradient (A: water with 0.1% formic acid; B: acetonitrile with 0.1% formic acid) at 
0.8 mL/min: 0 to 9.5 min, linear from 5% B to 100% B; 9.5 to 12.5 min, isocratic 100% B; 12.5 
to 12.6 min, linear from 100% B to 5% B; 12.6 to 15 min, isocratic 5% B. The injection volume 
was 2 μL.  
Samples were analysed by as described in Sendker et al. [34] with the following 
modifications: MS frequency was increased to 4 Hz; AutoMS2-mode was activated to target 
each Full-scan-mass-spectrum's three most abundant ions of m/z 200-1000 and minimum 
intensity of 2000 counts for up to two MS/MS experiments with the following setting: 624 
summations with 80 eV collision energy and 130 Vpp collision RF + 313 summations with 16 
eV and 130 Vpp + 313 summations with 16 eV and 300 Vpp were merged to one MS/MS 
spectrum. An ion that had been chosen twice as precursor ion was excluded from further MS/MS 
experiments for one typical chromatographic peak-base-width of 0.1 min. Full-scan MS- and 
MS/MS spectra were typically extracted from the mass-calibrated raw data by using the Dissect 
Compounds function of Compass Data Analysis 4.1 SR1. Spectra of the three most abundant 
residual chromatographic peaks (compounds 8-10) were extracted by integrating the 
corresponding time-ranges from a base peak chromatogram (mass range m/z 200-1000). Product 
ions were obtained from MS/MS experiments of protonated molecules or ammonium adduct 
ions, or from the Full-scan mass-spectra if no suitable MS/MS experiment was triggered. UV 
spectra were extracted by integrating the corresponding peaks from UV chromatograms at λ = 
230 nm or λ = 280 nm. All UV spectra and the Full-scan mass spectra of compounds 8-10 were 
corrected by subtracting from them the respective data of the respective peak borders. All other 
Full-scan mass spectra were corrected during the Dissect-Compounds-Processing by excluding 
any mass signal with deviating elution profile. Molecular formulas were determined using the 
Smart Formula tool of Data Analysis 4.1 SR1 under consideration of UV spectra and 
unambiguously determined ion formulas of smaller product ions. 
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Animals 
Ethical approval for the animal studies was obtained from the Animal Use Committee of the 
International Centre for Chemical and Biological Sciences (ICCBS), University of Karachi, 
Pakistan. In-house bred healthy adult female Wistar rats weighing 180-220 g (ICCBS) were 
utilised throughout the experiment. Animals were housed in standard environmental conditions 
of temperature, humidity, and light: dark cycle in clean polypropylene cages lined with husk bed 
and were fed on standard rodent diet with free access to water throughout the period of study. 
 
In Vitro Studies Enzyme Inhibition Studies: α – Glucosidase inhibition assay 
To determine the enzyme inhibition activity of the compound, the enzyme (α-glucosidase) from 
yeast (Saccharomyces cerevisiae) and the substrate (pNPG) was purchased from Sigma Aldrich, 
USA. The standard enzyme inhibition protocol used in the Enzyme Inhibition Laboratory of the 
Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, 
Pakistan, was adopted with some modifications [35]. The assay was performed using 96-well 
plates. Solutions of the inhibitor (in methanol) and that of the enzyme and the substrate (in 0.07 
M phosphate buffer, pH 6.8) were prepared using the standard procedures described for the 
assay. The enzyme (2.5 UmL-1) and the test compound (10 µL each) were pre-incubated at 37°C 
for 30 min before the addition of the substrate (10 µL) to each well of 96-well plate. The reaction 
mixture was incubated at 37°C for 30 min and stopped by adding 80 µL of 0.2 M Na2CO3. 
Acarbose and methanol were used as positive and negative control, respectively. The inhibitory 
activity of the compound was determined by measuring the p-nitro phenol released from pNPG 
at 405 nm using spectrophotometer (BioTek ELx800). The % inhibition was calculated by 
following equation:   
 
                    
 
IC50 value (Concentration of the inhibitor that inhibited 50% of α-glucosidase activity) 
was calculated using non-linear curve fitting program GraphPad PRISM 5.0 (San Diego, 
California, USA). 
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In Vivo animal Studies - Acute Oral Toxicity Evaluation 
The F. cretica L. extract was evaluated for acute oral toxicity in rats. A single oral administration 
of the extract at different doses (500 and 1000 mg/kg body weight), was given to two different 
groups consisting of five Wistar rats. The animals were observed for behavioural and toxic 
(mortality) effects continuously at short intervals of time, initially for 24 h, and then again at 48 
and 72 h, following extract administration. Serum biochemical parameters were also evaluated to 
check the toxicity to kidney and liver. 
 
Evaluation of Extract in Normal Healthy Rats 
Serum glucose levels of the animals were checked (after an overnight fasting period of 12–14 h,) 
by collecting the blood by snipping the tail vein using a glucometer Accu-Chek® (Roche 
Diagnostics, Mannheim, Germany). The animals were then divided into two groups (n = 
5/group). Group 1 served as the control, while group 2 was given a single oral dose of 500 mg/kg 
of the extract. Serum glucose levels of the animals were checked at 0, 1, 2, and 3 h. The values 
are expressed as mean ± SEM and p-value was calculated. 
 
Induction of Diabetes 
Rats were fasted for 12-14 h before the induction of the experimental diabetes. Non-insulin 
dependent diabetes mellitus (NIDDM) (Type II) was induced in rats by a single iv. injection of 
60 mg/kg of Streptozotocin, freshly prepared in cold citrate buffer (0.1 M, pH 4.5) followed after 
15 min by 120 mg/kg of freshly dissolved Nicotinamide in normal saline, injected 
intraperitoneally. Control rats were injected with an equivalent volume of citrate buffer only. 
Rats were given the glucose solution (5%) for 24 h. Diabetes was confirmed by the elevated 
levels of serum glucose after 72 h and then on day 7 by collecting fasting blood by snipping the 
tail vein, and serum glucose was determined by glucose oxidase-peroxidase (GOD-POD) 
method. Only those rats that have fasting blood glucose above 250 mg/dl were selected and used 
for the study. 
 
Study Design and Evaluation of TM in Experimental Animals 
Once the diabetes was confirmed the animals were divided randomly into five groups consisting 
of five animals each (n = 5) as follows: 
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 Group I: Non-diabetic control rats 
 Group II: Untreated diabetic control rats 
 Group III: Diabetic rats treated with F. cretica 250 mg/kg of body weight 
 Group IV: Diabetic rats treated with F. cretica 500 mg/kg of body weight 
 Group V: Diabetic rats treated with glibenclamide  
Group III and IV were given their respective treatments after one week of induction of 
diabetes. The first day of treatment was considered as Day 0. The treatment was continued till 
day 21. Freshly prepared solutions of extracts in distilled water (5 mL) were fed orally to the rats 
at a dose of 250 mg/kg and 500 mg/kg body weight, once a day for 21 days to group III and IV, 
respectively. Group I and II were given water only in place of extract, while group V was treated 
with the standard drug Glibenclamide (5 mg/kg).  
Body weights and serum sugar levels were determined weekly after an overnight fasting 
of 12-14 h. On day 22, the animals were anaesthetised after an overnight fasting using sodium 
pentothal (60 mg/kg), sacrificed, and their blood and organs were collected for further 
biochemical and histopathological examinations, respectively. 
 
Histopathological Studies 
Organs (Pancreases and Kidneys) were removed after dissection and placed in neutral buffered 
formalin (NBF, 10%) for fixation. Then, they were washed repeatedly with distilled water, 
dehydrated with increasing concentrations of 2- propanol, and embedded in paraffin. Sections (5 
μm thick) were made using microtome blades. The sections were deparaffinised, rehydrated with 
decreasing concentrations of 2-propanol, and mounted on glass slides. The slides were stained 
with haematoxylin and eosin, double blinded, and analysed.  
 
Statistical Analysis 
Data are expressed as the mean ± SEM. Statistical analyses were performed by using the 
Statistical Package for Social Science version 15.0 (SPSS) and GraphPad PRISM 5.0. Analysis 
of Variance (ANOVA) followed by unpaired and paired t-tests (2-tailed) were performed to 
detect any significant differences of means between and within group. Differences were 
considered as statistically significant for p-values less than or equal to 0.05 (p ≤ 0.05).  
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Results and Discussion 
The TM sample was prepared as a tea using freshly dried aerial parts as described by traditional 
healers [15]. The powder was lyophilised and was analysed using a modification of the methods 
described by Sendker et al. [34]. The corresponding LC/MS chromatographic fingerprint shows 
the main components of the extract (Fig. S1, Supporting Information). High-resolution MS and 
MS/MS spectra of these peaks were obtained from a representative LC-MS data set that was 
analysed using the Dissect Compounds algorithm of Data Analysis 4.0 (Bruker Daltonics). The 
algorithm detected 26 compounds. Expansions (Fig. 1), are focused on relevant peaks. The main 
peaks were tentatively characterised and correspond to glycosides of quercetin, kaempferol and 
isorhamnetin (Table 1 and Table S1, Supporting Information). The major compounds and their 
fragmentation patterns are shown in Fig. 2. Such glycosides have previously been detected in 
other Fagonia species [16, 29]. An unidentified iridoid-like compound (Fig. 1; peak 9; Fig. S2, 
Supporting Information) together with two sulphonated triterpenoid saponins (Fig. 1; peaks 17 
and 18; Fig. S3, Supporting Information) have been detected, and although not fully 
characterised, they are reported in this TM for the first time. Sulphonated saponins of the ursolic 
acid aglycone have been isolated from related species F. indica [35]. 
 
Fig. 1. LC/MS profile of F. cretica TM focused on relevant peaks., The dark line represents a 
base peak chromatogram of m/z 200-1000. Peaks 8, 9, and 10 have been detected from the BPC-
plot, the others by using the Dissect-Compounds-Algorithm of Bruker Data Analysis 4.1. 
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Table 1. The M/z’s for major compounds in the TM tea of F. cretica L by LC/MS in the positive ionisation mode. NI=Not identified, 
NFI=Not fully identified. 
Rt 
(min) 
Peak No m/z Adduct ion(s) MS/MS Fragment ions (m/z) 
(rel. Int. in percent) 
Molecular 
formula 
Identity 
1.278 7 257.0652 [M+H]+ MS1: 211.0600 (14), 193.0481 
(10), 147.0429 (12), 119.0487 
(7), 107.0489 (8) 
C11H13O6 Piscidic acid 
2.354 9 389.1078 [M+H]+ MS1: 371.0966 (17), 297.0534 
(8), 265.1421 (20), 213.0763 
[base peak]+ 
C16H21O10 Glycoside*. The 
aglycone is C10H13O5, 
m/z 213 Possible 
iridoid glycoside. 
3.371 11 611.1587 [M+H]+ MS1: 303.0561 (17) C27H31O16 Quercetin-3-O-
rutinoside (Rutin) 
3.603 12 595.1654 [M+H]+ MS2: 595.1642 (54), 449.1091 
(41), 287.0567 (100) 
C27H31O15 Keampferol-3-O-
rutinoside 
3.656 13 625.1787 [M+H]+ MS2: 625.1828 (62), 479.1186 
(32), 317.0683 (100); 
285.0358 (13) 
C28H33O16 Isorhamnetin-3-O-
rutinoside 
3.722 14 449.1100 [M+H]+ MS2: 449.1201 (37), 287.0574 
(100) 
C21H21O11 Kaempferol-3-
glucoside 
3.888 15 535.1096 [M+H]+ MS1: 287.0536 (9) C24H23O14 Kaempferol-3(6’-
malonylglucoside) 
3.964 16 565.1216 [M+H]+ MS1: 287.0506 (14) C25H25O15 Isorhamnetin 3-(6''-
malonylglucoside 
4.711 17 899.4061 [M+Na]+ MS1: 715.3730 (100), 
635.4144 (14), 553.3210 (59) 
C42H68NaO17S NFI: Saponin 
dihexoside of 
C30H48O7S 
4.895 18 985.4082 [M+Na]+ MS1: 801.3719 (100), 
553.323215 (26) 
C45H70NaO20S NFI: Saponin 
dihexoside, malonated 
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Fig. 2. Fragmentation patterns for the most abundant flavonoid glycosides characterised by 
LC/MS in the TM of F. cretica. 
In an acute toxicity study, the TM of F. cretica did not show any abnormal behaviour, no 
mortality was recorded up to the dose of 1,000 mg/kg body weight. Body weights and food 
consumption were similar to that of the control group and no significant differences were seen. 
No makers of toxicity were seen, which indicates that there were no gross pathological changes 
or any toxic effect on chronic administration of the extract, reflecting a good safety profile at a 
preliminary level. Thus, it can be concluded that F. cretica L. extract was safe at a dose of 1000 
mg/kg. The observed safety profile of the TM (Table S2, Supporting Information) is in keeping 
with its traditional use over long periods. 
Free radicals can be damaging and lead to various chronic diseases such as diabetes, 
arthritis, and asthma [37]. Using the DPPH radical assay, the free radical scavenging activity of 
the F. cretica L. TM did not show any significant inhibition (33%) compared to the standard 
control, Propyl gallate (90.01%). However the radical scavenging potential of phytochemically 
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derived ethyl acetate fraction of Fagonia Cretica L. is highly significant (93%). This reinforces 
the differences that exist between crude fractions, isolates and the actual TM administered and 
reinforces the need for studies that concentrate on the actual formulation of the herbal drug that 
is administered as a medicine. 
Competitive inhibition of the key hydrolysing enzymes of carbohydrate digestion (α-
glucosidase and α-amylase) present in the small intestine is an important approach for the 
management of diabetes [38] and is especially suited for a traditional Pakistani carbohydrate rich 
diet where carbohydrates contribute to over 60% of the usual Pakistani or South Asian diet [39]. 
The alpha glucosidase inhibitory effect of the TM was determined using α-glucosidase from 
yeast (Saccharomyces cerevisiae) using the substrate pNPG and 96-well plates and standardised 
protocols [35]. The standard α-glucosidase inhibitor acarbose was used as a control (Fig. 3).   
The IC50 value for α – glucosidase inhibition of 4.62 µg/ml (95% confidence limits between 
3.066 and 6.916 µg/ml) was obtained for the TM, while the IC50 value of acarbose was 17.4 
µg/ml (95% confidence limits between 11.44 and 25.7 µg/ml). Thus, inhibitory activity of the 
TM is comparable to that of the commercially available standard drug acarbose. Furthermore, 
common side effects of acarbose might include abdominal distention and pain and diarrhea, 
though such side effects are not associated with F. cretica as a TM [17]. 
 
Fig. 3. Effect of F. cretica and acarbose on α-glucosidase inhibitory activity assessed by 
spectrophotometric measurement at 405 nm of p-nitro phenol released from pNPG by α-
glucosidase from S. cerevisiae. Values are expressed as the mean ± SEM, n=3. 
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In this study a graded dose response on serum glucose levels was observed in normal 
healthy rats, when they were treated with the TM of F. cretica L. The dose-dependent 
hypoglycemic effects of the TM extract were observed in animals treated with 250 mg/kg and 
500 mg/kg of body weight, causing a 4.6% (p = 0.01) and 15.97% (p = 0.003) decrease in serum 
glucose levels, respectively, after 3 h of treatment. Serum glucose levels were recorded for 3 h 
and the results showed a gradual decrease in the plasma glucose levels when compared with the 
normal untreated group (Fig. 4). Since F. cretica can reduce blood glucose levels in 
normolgycaemic animals, there exists the possibility that high doses might precipitate a 
hypoglycaemic crisis and potential coma. However, such an effect has not been reported as a 
consequence of its use in TM [17]. The effects of the TM on repeated administration on a daily 
basis in STZ-NIC-induced diabetic rats is shown in Fig. 5.  
 
Fig. 4. Effects of F. cretica at 250 and 500 mg/kg on fasting blood glucose levels in female 
Wistar normoglycemic rats. Values are expressed as the mean ± SEM, n=5. 
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Fig. 5. Effects of F. cretica at 250 and 500 mg/kg and glibenclamide 5mg/kg on STZ/NIC 
diabetic rats given 5% glucose solution for 24 h. Values are expressed as the mean ± SEM, n=5. 
The blood glucose lowering effects of the plant extract were evaluated at two different 
doses (250 mg/kg and 500 mg/kg). The effect was found to be dose dependent. Both of the doses 
showed a fasting blood glucose lowering effect with a more pronounced and significant (p < 
0.05) effects observed with 500 mg/kg (45% decrease) at the end of the experimental period on 
day 21 when compared with that of the untreated diabetic group. The group treated with 250 
mg/kg did not show any significant decrease in serum sugar levels of the rats, while 
glibenclamide (GB) at a dose of 5mg/kg treated group reduced the serum glucose levels by 
56.4%. Serum glucose levels of different treatment groups on day 0 and day 21 are compared in 
Table 2. It should be noted that the blood glucose-lowering effect of the extracts in streptozocin-
induced diabetic rats was not a consequence of the alpha-glucosidase inhibitory activity, since 
these rats were fed with 5% glucose solution. While the hypoglycaemic target in diabetic rats is 
currently unknown, it is separate and distinct from the alpha-glucosidase inhibitory activity, and 
both activities may be additive in the clinical setting.   
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Table 2. Serum glucose levels of different treatment groups on day 0 and day 21. Effects of F. 
cretica at 250 and 500 mg/kg and glibenclamide 5 mg/kg on STZ/NIC diabetic rats given 5% 
glucose solution for 24 h. Values are expressed as the mean ± SEM, n=5. ***p<0.001.  
Sr. No. Treatment Groups 
Fasting Serum Glucose mg/dl 
Day 0  Day 21 
1. Normal Control (n=5) 88.00 ± 2.74 89.20 ± 1.20 
2. Untreated Diabetic (n=5) 294.00 ± 25.71 501.60 ± 9.10 
3. F.c. Treated 250 mg/kg (n=5) 246.00 ± 36.88 248.20 ± 21.58 
4. F.c. treated 500 mg/kg (n=5) 277.40 ± 32.80 152.40 ± 29.46*** 
5. GB Treated (n=5) 281.00 ± 6.979 122.60 ± 4.49*** 
 
Fig. 6. Histology of Pancreas of different treatment groups: a. Pancreas of normal control. b. 
Pancreas of untreated diabetic. c. Pancreas of F. cretica treated (500 mg/kg). d. Pancreas of F. 
cretica treated (250 mg/kg). e. Pancreas of GB treated. 
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The histological evaluation of the pancreatic tissue sections (H&E-stained) was evaluated 
in different experimental rat groups (normal control, untreated diabetic, F. cretica L. 250 mg/kg 
treated, F. cretica 500 mg/kg treated, and GB-treated) after 21 days of treatment. Pancreatic 
tissue images from selected groups are shown in Fig. 6. In normal control rats the pancreatic 
sections revealed that the islets of Langerhans were abundantly distributed having normal 
cellular characteristics (moderate to large size, with well-formed, oval to round shape) and 
diameter of pancreatic islets (Fig. 6a) when compared with other groups.  
In contrast, the pancreatic islets of the untreated diabetic rats were less distributed with 
irregular structure (reduced in size, neither round nor oval), (Fig. 6b). However, in the treated 
group with F. cretica L. extract (500 mg/kg), a moderate distribution of pancreatic islets was 
observed, and the islets appeared to have well-formed medium size with oval shape (Fig. 6c), 
while the treatment with the extract (250mg) also appeared similar but less in size and number of 
islet cells (Fig. 6d). The standard drug GB also restored such irregularity to the structure similar 
to that of the normal control group and improved the islets size (Fig. 6e). The results showed that 
the extracts were found to improve the pancreatic islets size, but the TM could not bring them to 
normal as seen in control rats. The administration of the streptozotocin caused a partial structural 
and dimensional damage to the islets of Langerhans, resulting in necrosis and infiltration of the 
β-cells and inhibit insulin secretion causing a state of diabetes in experimental rats. Treatment 
with positive control drug glibenclamide at the dose of 5 mg/kg reinstated the normal cellular 
structure and size of islets. The pancreas histology of the group treated with F. cretica extract 
(500 mg/kg) showed an improved architecture of the islets, greater persistence and lesser degree 
of necrotic changes when compared with that of the untreated diabetic group. 
Saleem at al. [31] have reported that extracts of F. Cretica act as DDP-4 inhibitors and 
suggest that extracts should be investigated for a hypoglycaemic activity in vivo, since the gliptin 
group of drugs, acting on DDP-4, are effective anti-diabetics. In the present work, we have 
chemically fingerprinted and demonstrated, for the first time, a hypoglycaemic effect of a TM 
made from F. cretica in normoglycaemic and streptozotocin-treated diabetic rats. Furthermore, 
we have shown, in this study, that there are additional activities which may augment any DPP-4 
inhibitory activity as previously described [31]. We have shown that the extracts composed of 
phenolic glycosides inhibit α-glucosidase activity to the same degree as the anti-diabetic drug 
acarbose. One of the components fingerprinted in the TM, quercetin-3-O-rutinoside (rutin), has 
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been reported to act as an inhibitor of α-glycosidase [40] and to decrease plasma glucose levels 
and increase insulin release in streptozotocin-treated rats [41]. Additionally, rutin increases 
glucose uptake in hepatocytes in vitro and in mice in vivo, implying its potential role in insulin 
resistance [42]. Quercetin, the aglycone of rutin, which may be a metabolite of the TM after 
ingestion, is believed to influence glycemic control in its own right, via reduction of intestinal 
glucose absorption and, probably, GLP-1 secretion [43].  
In addition, routine histological analysis of pancreatic sections confirmed that 
streptozotocin/nicotinamide treatment caused destruction of pancreatic islet cells. However, a 
histological examination of pancreatic sections from treatment groups showed that both the 
extract and Glibenclamide seemed to partially prevent this deterioration. This activity of 
glibenclamide has been observed in a previous study [44]. The mechanism of this protective 
effect is not clear; it may be limited to the processes involved in the mutagenic action of 
streptozotocin and it is not known whether this activity of the extract confers any clinical 
advantage. However, such a finding might suggest that it could confer additional benefits and 
should be investigated further. We believe that the current study supports the use of the TM 
prepared from F. cretica in the treatment of DM in Pakistan. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20 
 
References 
1. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate 
hyperglycaemia: report of a WHO/IDF consultation. Geneva, Switzerland; 2006 
2. Brownlee, M. Biochemistry and Molecular Cell Biology of Diabetic Complications. Nature 
2001; 414: 813-820 
3. Abdulkareem J, Quwaidhi Al. Epidemiological modelling of type 2 diabetes in Saudi Arabia: 
predicted trends and public health implications [dissertation]. University of Newcastle; 2013. 
4. Hussain M, Naqvi SBS, Khan MA, Rizvi M, Alam S, Abbas A, Akram M. Direct cost of the 
treatment of diabetes mellitus type 2 in Pakistan. Int J Pharm Pharm Sci 2014; 6: 261-262 
5. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack 
S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger 
PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, Davidson MH. American 
association of clinical endocrinologists’ comprehensive diabetes management algorithm 
consensus statement. Endocr Pract 2013; 19: 536-557 
6. Rutten G, Verhoeven S, Heine RJ, de Grauw WJC, Cromme PVM, Reenders K, van 
Ballegooie E, Wiersma TJ. Dutch college of general practitioners' guidelines on type 2 diabetes 
mellitus. Huisarts Wet 1999; 42: 67-84 
7. International Diabetes Federation. Http://www.idf.org/membership/mena/pakistan. Accessed 
02 December, 2016 
8. Campbell LK, White JR, Campbell PK. Acarbose: its role in the treatment of diabetes 
mellitus. Ann Pharmacother 1996; 30: 1255-1262 
9. Ceriello A. Postprandial hyperglycemia and diabetes complications is it time to treat? Diabetes 
2005; 54: 1-7 
10. Kusunoki Y, Katsuno T, Myojin M, Miyakoshi K, Ikawa T, Matsuo T, Ochi F, Tokuda M, 
Murai K, Miuchi M, Hamaguchi T, Miyagawa J, Namba M. Effect of additional administration 
of acarbose on blood glucose fluctuations and postprandial hyperglycaemia in patients with type 
2 diabetes mellitus under treatment with alogliptin. Endocr J 2013; 60: 431-439 
11. Zhou J, Li H, Zhang X, Peng Y, Mo Y, Bao Y, Jia W. Nateglinide and acarbose are 
comparably effective reducers of postprandial glycemic excursions in Chinese 
antihyperglycemic agent–naive subjects with type 2 diabetes. Diabetes Technol Ther 2013; 15: 
481-488 
 12. Kalra S, Gupta Y. The insulin: glucagon ratio and the choice of glucose-lowering drugs. 
Diabetes Ther 2016; 7: 1–9 
  
 21 
 
13. Patwardhan B. Traditional medicine: modern approach for affordable healthcare. World 
Health Organization. WHO Geneva, Switzerland; 2005. Available at 
http://www.who.int/intellectualproperty/studies/B.Patwardhan2.pdf. Accessed 02 December, 
2016. 
14. Shaikh BT, Hatcher J. Complementary and alternative medicine in Pakistan: prospects and 
limitations. Evid Based Complement Alternat Med 2005; 2: 139–142 
15. Nazir I, Rahman N,  Alvi Z, Hafizur M, Rahman H, Sheridan H. Use of herbal plants to treat 
diabetes mellitus in Pakistan. An ethnopharmacological survey in the city of Bahawalpur and the 
Cholistan desert. London BioNat. , University of East London, March 12th Poster presentation 
2013. 
16. Qureshi H, Asif S, Ahmed H, Al-Kahtani HA, Hayat K. Chemical composition and 
medicinal significance of Fagonia Cretica: a Review.  Nat Prod Res 2016; 30: 625-639  
17. Chopra RM, Handa KL, Kapur LD ,Chopra IC. Indigenous Drug of India. 2nd edition. New 
Delhi, India: Academic Press; 1982: 507 
18.  Nadkarni KM. Dr. K. M. Nadkarni's Indian materia medica: with Ayurvedic, Unani-tibbi, 
Siddha, allopathic, homeopathic, naturopathic & home remedies, appendices & indexes, Vol. 2. 
Popular Prakashan; 1954 
19 Ahmad M, Khan MA, Arshad M, Zafar M. Ethnophytotherapical approaches for the treatment 
of diabetes by the local inhabitants of district Attock (Pakistan). Ethnobotanical Leaflets 2004; 1: 
7.  
20 Ahmad M, Qureshi R, Arshad M, Khan, MA, Zafar M. Traditional herbal remedies used for 
the treatment of diabetes from the district of Attock (Pakistan). Pak J Bot 2009; 41: 2777-2782  
21.  Razi MT, Asad MH, Khan T, Chaudhary MZ, Ansari MT, Arshad MA, Saqib QN. 
Antihaemorrhagic potentials of Fagonia cretica L. against Naja naja karachiensis (black Pakistan 
cobra) venom. Nat Prod Res 2011; 25: 1902-1907 
22. Hussain, A., Zia M, Mirza B. Cytotoxic and antitumor potential of Fagonia cretica L. Turk J 
Biol 2007; 31: 19-24 
23. Rawal AK, Nath DK, Yadav N, Pande S, Meshram SU, Biswas SK. Rubia cordifolia, 
Fagonia cretica linn and Tinospora cordifolia exert anti-inflammatory properties by modulating 
platelet aggregation and VEGF, COX-2 and VCAM gene expressions in rat hippocampal slices 
subjected to ischemic reperfusion injury. Int J Appl Res Nat Prod 2009; 2: 19-26 
24. Rawal, AK, Muddeshwar MG, Biswas SK. Rubia cordifolia, Fagonia cretica linn and 
Tinospora cordifolia exert neuroprotection by modulating the antioxidant system in rat 
hippocampal slices subjected to oxygen glucose deprivation. BMC Complementary Altern Med 
2004; 4:11 
 
 22 
 
25. Sharma K, Zafar R. Occurrence of taraxerol and taraxasterol in medicinal plants. 
Pharmacogn Rev 2015; 9: 19-23   
26. Shishodia S, Majumdar S, Banerjee S, Aggarwal B. Ursolic acid inhibits nuclear factor-
kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase 
and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix 
metalloproteinase 9, and cyclin D1. Cancer Res 2003; 63: 4375-4383 
27. Abdel KSM, Miyase T, El-Ashaal HA, Meleek FR. Triterpenoid saponins from Fagonia 
cretica. Phytochemistry 2000; 54: 853–859 
28. Anjum MI, Ahmed E, Jabbar A, Malik A, Ashraf M, Moazzam M, Rasool MA. 
Antimicrobial Constituents from Fagonia cretica. Jour Chem Soc Pak 2007; 29: 634-639 
29.  El- Negoumy SI, Al-Wakeel SAM, El- Hadidi MN, Saleh NAM. The flavonoids of the 
Fagonia arabica-complex (Zygophyllaceae).  Phytochemistry 1986; 25: 2423–2424 
30. Lam M, Carmichael AR, Griffiths HR. An aqueous extract of Fagonia cretica induces DNA 
damage, cell cycle arrest and apoptosis in breast cancer cells via FOXO3a and p53 expression. 
PLoS One 2012; 7: e40152 
31. Saleem S , Jafri L , ul Haq I , Chang LC , Calderwood D , Green BD , Mirza B. Plants 
Fagonia cretica L. and Hedera nepalensis K. Koch contain natural compounds with potent 
dipeptidyl peptidase-4 (DPP-4) inhibitory activity. J Ethnopharmacol 2014; 156: 26-32. 
32. Sheridan H, Krenn L, Jiang R, Sutherland I, Ignatova S, Marmann A, Liang XM, Sendker J. 
The potential of metabolic fingerprinting as a tool for the modernisation of TCM preparations. J 
Ethnopharmacol 2012; 140: 482-491 
33. Sheridan H, Kopp B, Krenn L, Guo D, Sendker J.Traditional Chinese herbal medicine 
preparation: invoking the butterfly effect. Science 2015; 350: S64-S66 
34. Sendker J, Ellendorff T, Hölzenbein A. Occurrence of benzoic acid esters as putative 
catabolites of prunasin in senescent leaves of Prunus laurocerasus. J Nat Prod 2016; 79: 1724-
1729 
35. Shaker KH, Bernhardt M, Elgamal MHA, Seifert K. Sulfonated triterpenoid saponins from 
Fagonia indica. Z Naturforsch 2000; 55c: 520-523  
36. Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and health. Int J 
Biomed Sci 2008; 4: 89-96 
37. Wongsa P, Chaiwarit J, Zamaludien A. In vitro screening of phenolic compounds, potential 
inhibition against α-amylase and α-glucosidase of culinary herbs in Thailand. Food Chem 2012; 
131: 964-971 
38. Kalra, S. Alpha glucosidase inhibitors. J Pak Med Assoc 2014; 64: 474-476 
 23 
 
39. Ma HY, Gao HY, Sun L, Huang J, Xu XM, Wu LJ. Constituents with α-glucosidase and 
advanced glycation end-product formation inhibitory activities from Salvia miltiorrhiza Bge. J 
Nat Med 2011; 65: 37-42 
40. Jo SH, Ka EH, Lee HS, Apostolidis HD, Jang HD, Kwon YI. Comparison of antioxidant 
potential and rat intestinal α-glucosidases inhibitory activities of quercetin, rutin, and 
isoquercetin. Int J Appl Res Nat Prod 2009; 2: 52-60.  
41. Kamalakkannan N, Prince PSM. Antihypercaemic and antioxidant effect of rutin, a 
polyphenolic flavonoid, in streptozotocin-induced diabetic wistar rats. Basic Clin Pharmacol 
Toxicol 2006; 98: 97-103 
42. Lee CC, Hsu WH, Shen SR, Cheng YH, Wu SC. Fagopyrum tataricum (buckwheat) 
improved high-glucose-induced insulin resistance in mouse hepatocytes and diabetes in fructose-
rich diet-induced mice. Exp Diabetes Res 2012; 2012: 375673 
43. Chang CLT, Lin Y, Bartolome AP, Chen YC, Chiu SC, Yang WC. Herbal therapies for type 
2 diabetes mellitus: chemistry, biology, and potential application of selected plants and 
compounds. Evid Based Complement Alternat Med 2013; 2013:378657 
40. Rabbani SI, Devi K, Khanam S. Protective role of glibenclamide against nicotinamide-
streptozotocin induced nuclear damage in diabetic Wistar rats. J Pharmacol Pharmacother 2010; 
1: 18-23 
 
 
